Clinical trial
Single-Dose Oral Tizanidine Premedication for Laryngeal Mask Airway Insertion Conditions and Ambulatory Recovery Quality in Sevoflurane-Based Anesthesia: A Randomized Double-Blind Placebo-Controlled Trial
NCT07921602 is registered in ClinicalTrials.gov with Beni-Suef University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Single-Dose Oral Tizanidine Premedication for Laryngeal Mask Airway Insertion Conditions and Ambulatory Recovery Quality in Sevoflurane-Based Anesthesia: A Randomized Double-Blind Placebo-Controlled Trial
- Lead sponsor
- Beni-Suef University
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- May 31, 2027
- Enrollment
- 110 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
airway management
Arms
As registered; 2 arms.
-
Tizanidine 4 mg
Participants receive a single preoperative oral dose of tizanidine 4 mg (encapsulated in an opaque gelatin capsule) with a small sip of water (\< 30 mL) 60-90 minutes prior to induction of anesthesia.
-
Placebo Control
Participants receive a single preoperative oral matching placebo capsule with a small sip of water (\< 30 mL) 60-90 minutes prior to induction of anesthesia.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Proportion of Patients with Excellent Laryngeal Mask Airway (LMA) Insertion Conditions at First Attempt
Evaluated immediately after the first insertion attempt using a validated 5-domain composite scale (jaw relaxation, ease of insertion, patient movement, coughing/gagging, and laryngospasm/obstruction). Each domain is scored from 1 (optimal) to 3 (worst), yielding a total composite score range of 5 (optimal) to 15 (worst). 'Excellent' insertion condition is pre-specified as a total composite score of 5 to 7.
Lead sponsor's other trials
Beni-Suef University, most recent start first.
+343 more trials See the organization page